This section of the website is intended exclusively for qualified healthcare professionals (HCPs).

The materials provided within this Medical Affairs page are intended for scientific exchange and medical education purposes only. Access to this section does not constitute an offer to promote or sell any product for any unapproved use. Any discussion of unapproved uses herein is provided solely in response to professional interest in scientific and clinical information.

Content in this section may include:

Discussion of uses that are not approved by regulatory authorities in one or more jurisdictions
Scientific data relating to investigational or off-label uses

Regulatory approval and labeling may vary by country. Safety and effectiveness for certain uses discussed may not have been established by regulatory authorities in your jurisdiction.

This information is not intended as promotional material and is not intended to provide medical advice to patients.

By selecting “I Agree,” you certify that:

You are a licensed healthcare professional authorized to prescribe, purchase, or administer medical products in your country
You are seeking this information for professional, scientific, or educational purposes
You understand that some information may relate to uses that are not approved in your country

If you cannot confirm all of the above statements, please exit this section of the website.

I agree

The following articles/clinical evidence describes some uses of IRRAFlow that are not approved by the FDA, and the safety and effectiveness of any unapproved use(s) have not been established.

The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:

The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.

For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://irras.com/product/eifu/

The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications:

Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine

Click anywhere to continue

This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.

The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:

The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.

Click anywhere to continue

This reference material is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not cleared by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.

The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:

The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.

The ACE Society received financial support from IRRAS. IRRAS did not control the content of the reference material. The views expressed are those of the authors.

The following officers and former officers of the ACE Society were paid consultants who have received compensation from IRRAS.

Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo

Click anywhere to continue